Search results for "Malalties hematològiques"

showing 4 items of 4 documents

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

2022

Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 …

*Pfizer-BioNTech BNT162b2Cancer ResearchCOVID-19 Vaccines*Hematological malignanciesAutologous stem cell transplantationAntibodies ViralBreakthrough SARS-CoV-2 infectionModerna mRNA-1273Cohort StudiesHematological malignancies*Moderna mRNA-1273Correlates of protection*VaccineHumansProspective StudiesVacunacióPfizer-BioNTech BNT162b2Molecular BiologyBNT162 Vaccine*Immunocompromised patients*Correlates of protectionSARS-CoV-2VaccinationHematologic diseasesCOVID-19Hematology*Breakthrough SARS-CoV-2 infectionHematologic DiseasesSARS-CoV-2 vaccinesAllogeneic stem cell transplantationVirusOncologyMalalties hematològiquesImmunocompromised patients*SARS-CoV-2 vaccines*Autologous stem cell transplantation*COVID-19Vaccine*Allogeneic stem cell transplantationJournal of Hematology & Oncology
researchProduct

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

2014

This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies. Patients at least six months post transplant were treated with deferasirox at a starting dose of 10 mg/kg/day for 52 weeks or until serum ferritin was less than 400 ng/mL on two consecutive occasions. Thirty patients were enrolled and 22 completed the study. A significant reduction from baseline in median serum ferritin and in liver iron concentration at 52 weeks was observed in the overall population: from 1440 to 755.5 ng/mL (P=0.002) and from 14.5 to 4.6 mg Fe/g dw (P=0.0007), respectively. Reduction in serum fe…

AdultMalemedicine.medical_specialtyLiver Iron ConcentrationIron Overloadmedicine.medical_treatmentPopulationStem cellsHematopoietic stem cell transplantationIron Chelating AgentsBenzoatesGastroenterologyYoung Adultchemistry.chemical_compoundInternal medicinemedicineHumansTransplantation HomologousAdverse effecteducationProspective cohort studyAgededucation.field_of_studyCreatininebusiness.industryDeferasiroxHematopoietic Stem Cell TransplantationHematologic diseasesTransfusion ReactionArticlesHematologyMiddle AgedTriazolesSurgeryTransplantationDeferasiroxTreatment OutcomechemistryMalalties hematològiquesFerritinsFemaleCèl·lules marebusinessmedicine.drug
researchProduct

Buccodental health and oral mucositis. Clinical study in patients with hematological diseases

2006

Podeu consultar la versió en castellà a http://hdl.handle.net/2445/117376

RadiotherapyHematologic diseasesRadioteràpia:CIENCIAS MÉDICAS [UNESCO]chemoradiotherapyMucosa oralmucositisMalalties hematològiquesUNESCO::CIENCIAS MÉDICASQuimioteràpiaChemotherapyMalignant hematological diseasesOral mucosabuccodental status
researchProduct

Mediterranean Diet and White Blood Cell Count—A Randomized Controlled Trial

2021

We aimed to assess the effects of the antioxidant-rich Mediterranean diet (MedDiet) on white blood cell count. Our study population included participants in the PREvención con DIeta MEDiterránea study (average age 67 years old, 58% women, high cardiovascular risk). We assessed whether a MedDiet intervention enriched in extra-virgin olive oil or nuts, versus a low-fat control diet, modified the incidence of leukocytosis (&gt

medicine.medical_specialtyHealth (social science)Mediterranean dietPlant ScienceTP1-1185030204 cardiovascular system & hematologyLower riskHealth Professions (miscellaneous)MicrobiologyGastroenterologyArticle03 medical and health sciences0302 clinical medicineMediterranean cookingpreventionWhite blood cellInternal medicineMediterranean dietCuina mediterràniamedicineLeukocytosisLeucocytes030304 developmental biology0303 health sciencesLeukopeniaLeucòcitsbusiness.industryIncidence (epidemiology)leukopeniaChemical technologyHazard ratioHematologic diseasesmedicine.anatomical_structureleukocytosisMalalties hematològiquesrandomized controlled trialPopulation studymedicine.symptombusinessFood Sciencewhite blood cell countFoods
researchProduct